Table 2. IC₅₀ (μM) values ^a for compounds 8(a–u) on selected human cancer cell lines.

Compound	DU-145 b	A549 c	Hela d	MCF-7 e
8a	6.261	4.467	4.571	14.86
8b	11.13	12.65	19.95	16.50
8c	1.452	1.346	4.545	9.833
8d	6.130	3.251	10.95	13.00
8e	11.33	10.97	13.60	18.94
8f	10.69	8.800	15.32	19.35
8g	5.280	1.052	9.440	14.95
8h	4.720	1.211	4.852	11.63
8i	2.924	2.239	3.090	10.22
8j	2.190	1.570	14.90	7.609
8k	1.820	1.349	2.042	8.667
8l	2.443	1.750	3.076	5.167
8m	1.076	0.861	1.219	1.807
8n	3.250	1.138	3.020	3.388
8o	11.97	9.897	14.56	13.58
8p	10.79	6.458	11.85	16.33
8q	1.500	0.933	1.479	2.692
8r	1.288	1.014	3.243	7.125
8s	2.630	2.291	10.93	9.600
8t	4.168	2.884	3.715	18.860
8u	13.630	13.040	16.350	22.780
Nocodazole	1.259	1.393	1.611	1.086

^a50% inhibitory concentration after 48 h of drug treatment.

^bHuman prostate cancer.

^cHuman lung cancer.

^dHuman cervical cancer.

^eHuman breast cancer.